Advancing the use of RWE with our research collaborators
Proven track record and offerings across every stage of the drug life cycle
Discovery & early development
Our real-world evidence bridges the gap between genomics and clinical outcomes. Integrating previously siloed data modalities unlocks new possibilities for real-world data earlier in the life cycle.
Our real-world evidence is informing the design of clinical trials, including helping researchers better model trial inclusion criteria. This can result in fewer protocol amendments, an increased pace of enrollment, and support the shift to more pragmatic trials.
As the pioneer in real-world evidence for oncology, Flatiron has a longstanding track record of supporting RWE submissions to regulators globally. Since 2016, the FDA and Flatiron have worked directly through a research collaboration to advance the use of real-world evidence to inform regulatory decision-making.
Flatiron evidence plays a crucial role in post-approval efforts. Beyond post-marketing requirements, Flatiron data supports market tracking, assessment of real-word outcomes, and label updates in both Europe and the U.S.
HTA bodies around the world have assessed our real-world data as part of reimbursement evaluations for new medicines. Today, Flatiron real-world data supports access for patients on a global scale.
Your destination for the latest thought leadership on real world data uses, applications and case studies.
The world’s leading biopharma companies use Flatiron real-world data products to accelerate R&D and access, make research more inclusive, and make healthcare more sustainable.
Add-ons to our products:
Real-world outcome variables
Flatiron’s real-world outcomes variables are used to derive real-world endpoints. They account for the inherent complexities of patient outcomes specific to each cancer type.